FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Corcepts Lifyorli Combo in Platinum-Resistant Ovarian Cancer Approved

[ Price : $8.95]

FDA approves Corcept Therapeuticss cortisol-modulating drug Lifyorli (relacorilant) in combination with nab-paclitaxel for patient...

HELP Republican Senators Urge FDA Mifepristone Action

[ Price : $8.95]

Five Republicans on the Senate HELP Committee urge FDA to crack down on companies they say are illegally selling chemical abortion...

5 Key Points in New FDA Weight Loss Device Guidance

[ Price : $8.95]

Two Hogan Lovells attorneys highlight five areas in a new FDA final guidance on weight loss devices.

4 CGMP Issues in the Yangzhou Company Inspection

[ Price : $8.95]

FDA warns Chinas Yangzhou H&R Plastic Daily Chemical Company about CGMP violations in its production of finished drugs.

QS Violations at IsoTis OrthoBiologics

[ Price : $8.95]

FDA warns Irvine, CA-based IsoTis OrthoBiologics about Quality System violations in its production of Accell-branded resorbable ca...

More Conflict of Interest Transparency Needed: GAO

[ Price : $8.95]

The Government Accountability Office recommends that FDA take steps to publicly disclose how it resolves conflict of interest and ...

Meaning of Prasads Departure Debated

[ Price : $8.95]

Three experts express differing views on the reasons for and the impact of the departure of CBER director Vinay Prasad from FDA fo...

Race to the Bottom Generic Model Threatens Quality/Supply: Expert

[ Price : $8.95]

A Brookings commentary warns that intense price competition in the U.S. generic drug market is undermining manufacturing quality a...

Ocugen Reports Positive Phase 2 Data for Vision Loss Gene Therapy

[ Price : $8.95]

Ocugen announces positive 12-month results from a mid-stage clinical trial of its experimental gene therapy OCU410, aimed at treat...

ImmunityBio Warning Letter Over Misleading Promotion of Anktiva

[ Price : $8.95]

FDA sends a Warning Letter to ImmunityBio, citing misleading promotional claims about its cancer therapy Anktiva (nogapendekin alf...